You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

21 Items
Cancer Type: Breast, Central Nervous System, Gastrointestinal, Colorectal, Esophagus, Gastric / Stomach, Hepatobiliary / Liver / Bile Duct, Pancreas, Genitourinary, Bladder / Urothelial, Prostate, Gynecologic, Cervix, Endometrial, Ovary, Head and Neck, Lung, Small Cell     
Intent: Adjuvant, Curative, Palliative
Jun 2019
Cancer Type: Breast, Central Nervous System, Gastrointestinal, Colorectal, Esophagus, Gastric / Stomach, Hepatobiliary / Liver / Bile Duct, Pancreas, Genitourinary, Bladder / Urothelial, Prostate, Gynecologic, Cervix, Endometrial, Ovary, Head and Neck, Lung, Small Cell     
Intent: Adjuvant, Curative, Palliative
May 2019
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    daSAtinib - PH+ ALL, with specific criteria
May 2019
Cancer Type: Gastrointestinal, Esophagus, Gastric / Stomach     
Intent: Palliative
Nov 2017
Cancer Type: Gastrointestinal, Neuroendocrine (GI)     
Intent: Palliative
Jun 2019
Cancer Type: Gastrointestinal, Colorectal     
Intent: Palliative
Jun 2017
Cancer Type: Gastrointestinal, Colorectal, Small bowel and appendix     
Intent: Palliative
Funding:
New Drug Funding Program
    Irinotecan - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Irinotecan - Second Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Bevacizumab (Biosimilar) - First Line - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
Updated
Aug 2019
Cancer Type: Gastrointestinal, Colorectal     
Intent: Palliative
Aug 2018
Cancer Type: Gastrointestinal, Colorectal, Small bowel and appendix     
Intent: Palliative
Funding:
New Drug Funding Program
    Irinotecan - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Panitumumab - In Combination with Chemotherapy for First Line Metastatic Colorectal Small Bowel or Appendiceal Cancer
Aug 2018
Cancer Type: Gastrointestinal, Pancreas     
Intent: Palliative
Funding:
New Drug Funding Program
    Oxaliplatin and Irinotecan - Advanced Pancreatic Cancer (FOLFIRINOX)
May 2017
Cancer Type: Gastrointestinal, Colorectal     
Intent: Palliative
Jun 2019